Pfizer announced on Monday that it is halting development of its oral weight-loss pill after one patient experienced liver issues. The company said it halted development of danuglipron, an oral drug ...

A study reveals advances in the understanding and treatment of liver fibrosis, a serious complication in the context of metabolic fatty liver disease, also known as MASLD (metabolic ...

An international team of researchers bioengineering human liver tissues uncovered previously unknown networks of genetic-molecular crosstalk that control the organ's developmental processes – greatly ...

The liver is accountable for metabolizing most medications and is therefore one of the primary tissues affected by adverse drug reactions. Most classes of medicine can cause drug-induced liver injury ...

Pedestrians walk by the Pfizer corporate headquarters in New York City (2020). On Monday the company said it was discontinuing development of a weight-loss drug in pill form. File Photo by John ...

FILE PHOTO: The headquarters of the U.S. Food and Drug Administration is shown in Silver Spring near Washington Dec 8 (Reuters) - The U.S. Food and Drug Administration has qualified the first ...

The FDA has qualified its first artificial intelligence tool to help drug developers evaluate fatty liver disease in their clinical trials. The agency gave a green light to the AI-Based Histologic ...

VivoSim Labs' NAMkind™ platform shows 87.5% predictive accuracy for liver toxicity, enhancing drug safety and reducing development costs. VivoSim Labs, Inc. announced the successful performance of its ...

Cytotheryx, a growing Rochester biotech firm working on treatments for liver disease, recently received $60 million in ...